





Readable

Pharmaceuticals and Security: Strengthening Industry Engagement

Future directions in public-private collaboration for health security

Head of the Centre for Global Health Policy, University of Sussex

Date: Friday 7 February 2014

Time: 9:00am-5:00pm

Venue: Conference Room @ The Royal Institution of Great Britain
21 Albemarle Street, Mayfair, London W1S 4BS

For details of how to register please visit:

www.sussex.ac.uk/globalhealthpolicy

US

University of Sussex
Centre for Global Health Policy

Public health need be secured against acute and chronic health care, infectious diseases, and endemic infectious diseases. The health care system and global health initiatives have sought to enhance the availability of new medicines and vaccines. Promoted by the health care industry, financial, and commercial interests, the pharmaceutical industry. In the case of infectious diseases, the UK and US governments established new agencies with pharmaceutical companies in developing medical care measures. At the international level, global health initiatives such as Aeras, GAVI and the Global Fund work in increasing the availability of medicines and vaccines.

Agenda

Chair : Prof Sir Stephen Elbe, Chief Executive of Global Health Policy

09:00 – 09:30	Coffee/Tea and Registration
09:30 – 10:00	Welcome and Participants' Introductions
10:00 – 10:30	Panel 1: Public-Private Collaboration in Health Security
10:30 – 12:00	Session 1: Engaging the Pharmaceutical Industry: Incentives, Successes and Challenges Topic : • What incentives have been used to engage pharmaceutical companies in health security collaborations? • Which incentives have worked best for: biotechnology companies, pharmaceutical companies, and companies from middle-income countries? • Have government investments in antiviral stockpiling helped foster collaborations or created reservations?
12:00 – 13:30	Lunch (provided)
13:30 – 15:00	Session 2: Where is the Business Case in Health Security? Commercial Evidence and Perspectives Topic : • What areas of health security have a strong business case for: biotechnology companies, pharmaceutical companies, and companies from middle-income countries? • How have incentives provided by governments/global institutions (including the creation of stockpiles) strengthened the business case? • What capabilities are companies looking for governments and global health institutions to provide?
15:00 – 15:30	Coffee/Tea
15:30 – 16:30	Session 3: Perspectives on Partnership Models for Effective Decision Making in Global Health Security Topic : • Are the prospects for public-private collaborations in the area of health security improving or weakening? • Moving forward, where does the partnership model need to be modified and/or improved? • Do we need to also start thinking beyond the partnership approach to other models for pharmaceutical innovation?
16:30 – 16:45	Close and Thank You

The Centre for Global Health Policy, University of Sussex